14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
On December 6, 2019, a sharply divided panel of the Second Circuit (covering New York, Connecticut, ...
Read More >
Arnall Golden Gregory LLP is pleased to provide you with the Compliance News Flash, which includes c...
Read More >
In 2019, the Department of Labor (DOL) continued its trend of providing limited advance guidance und...
Read More >
In today’s edition of Daily Compliance News: Top Vatican AML official leaves post. (YahooNews) SEC...
Read More >
Seyfarth Synopsis: As part of Governor Cuomo’s New York Forward plan, “Phase One” industries in f...
Read More >
For decades, federal wage and hour regulations have required that non-discretionary bonuses paid to ...
Read More >